| |
Persistent oligoarticular JIA (n = 78)
|
Extended oligoarticular JIA (n = 56)
|
Polyarticular JIA RF- (n = 103)
|
Polyarticular JIA RF + (n = 26)
|
ERA (n = 62)
|
Total (n = 325)
|
|---|
|
c-DMARD
|
|
Number of distinct c-DMARD prescribed (n, %)
|
|
0
|
40 (51%)
|
6 (11%)
|
0 (0%)
|
0 (0%)
|
7 (11%)
|
53 (16%)
|
|
1
|
32 (41%)
|
37 (66%)
|
65 (63%)
|
16 (62%)
|
38 (62%)
|
188 (58%)
|
|
≥ 2
|
6 (8%)
|
13 (23%)
|
37 (37%)
|
10 (38%)
|
17 (27%)
|
84 (26%)
|
|
c-DMARD types (n, %)
|
|
Methotrexate
|
34 (44%)
|
45 (80%)
|
99 (96%)
|
26 (100%)
|
39 (63%)
|
243 (75%)
|
|
Sulfasalazine
|
< 5 (< 6%)
|
7 (12%)
|
21 (20%)
|
< 5 (< 19%)
|
30 (48%)
|
66 (20%)
|
|
HCQ
|
5 (6%)
|
6 (11%)
|
16 (16%)
|
6 (23%)
|
< 5 (< 8%)
|
36 (11%)
|
|
Leflunomide
|
< 5 (< 6%)
|
6 (11%)
|
13 (13%)
|
< 5 (< 19%)
|
< 5 (< 8%)
|
26 (8%)
|
|
c-DMARD therapy combination
|
|
Double c-DMARD
|
5 (6.4%)
|
8 (14%)
|
27 (26%)
|
9 (35%)
|
12 (19%)
|
61 (19%)
|
|
Triple c-DMARD
|
0
|
< 5 (< 9%)
|
< 5 (< 5%)
|
< 5 (< 19%)
|
0
|
5 (2%)
|
|
b-DMARD
|
|
Number of distinct b-DMARD prescribed (n, %)
|
|
0
|
69 (88%)
|
31 (55%)
|
40 (39%)
|
8 (31%)
|
30 (48%)
|
178 (55%)
|
|
1
|
9 (12%)
|
22 (39%)
|
46 (45%)
|
13 (50%)
|
21 (34%)
|
111 (34%)
|
|
≥ 2
|
0
|
< 5 (< 9%)
|
17 (16%)
|
5 (19%)
|
11 (18%)
|
36 (11%)
|
|
b-DMARD types (n, %)
|
|
Etanercept
|
< 5 (< 6%)
|
14 (25%)
|
44 (43%)
|
15 (58%)
|
25 (40%)
|
102 (31%)
|
|
Adalimumab
|
< 5 (< 6%)
|
9 (16%)
|
21 (20%)
|
< 5 (< 19%)
|
13 (21%)
|
51 (16%)
|
|
Tocilizumab
|
< 5 (< 6%)
|
< 5 (< 9%)
|
11 (11%)
|
< 5 (< 19%)
|
< 5 (< 8%)
|
17 (5%)
|
|
Othersa
|
0
|
< 5 (< 9%)
|
13 (13%)
|
< 5 (< 19%)
|
10 (16%)
|
28 (9%)
|
- JIA Juvenile idiopathic arthritis, RF Rheumatoid factor negative, RF Rheumatoid factor positive, ERA Enthesis-related arthritis, c-DMARD Conventional disease anti-rheumatic drugs, b-DMARD Biologic disease anti-rheumatic drugs, HCQ Hydroxychloroquine
- aGolimumab, infliximab, tofacitinib, abatacept, and secukinumab
